Lonza has enhanced its advanced synthesis capabilities by integrating ADC technologies obtained from Synaffix, including GlycoConnect, HydraSpace, and toxSYN linker payloads, to support the development of more effective bioconjugates like next-generation dual-payload ADCs. This expansion strengthens Lonza's position in the biopharmaceutical market by offering comprehensive services for drug developers working on innovative bioconjugate therapies.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



